Kidney Week ‘22 Updates

ASN Scientific Briefing & Reception

ProKidney Corp.
Nasdaq: PROK

3 November 2022

Forward-looking Statements

This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to financial results, future performance, development and commercialization of products, if approved, the potential benefits and impact of the Company’s products, if approved, potential regulatory approvals, and the size and potential growth of current or future markets for the Company’s products, if approved. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A ordinary shares on the Nasdaq; the inability to implement business plans, forecasts, and other expectations or identify and realize additional opportunities, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of Company to compete with other companies currently marketing or engaged in the biologics market and in the area of treatment of kidney diseases; the size and growth potential of the markets for the Company’s products, if approved, and its ability to serve those markets, either alone or in partnership with others; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company’s intellectual property rights; uncertainties inherent in cell therapy research and development, including the actual time it takes to initiate and complete clinical studies and the timing and content of decisions made by regulatory authorities; the impact of COVID-19 or geo-political conflict such as the war in Ukraine on the Company’s business; and other risks and uncertainties indicated from time to time in the Company’s filings with the Securities and Exchange Commission. The Company cautions readers that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

What is ProKidney?

REACT® Aims to be the Disruptive World Leader in Treating Chronic Kidney Disease (CKD)

The Problem

- $130 billion Medicare cost to care for the 40 million CKD/ESKD patients in U.S.
- 75 million CKD patients in the U.S. and EU

The Goal

- Stabilize, or reverse the decline of kidney function to delay or prevent dialysis / kidney transplantation
- Reduce the lifetime cost of care for CKD afflicted patients

The Product

- REACT™ utilizes proprietary autologous cell therapy harvested from the patient's own kidney
- REACT™ includes three specific cell types with the potential to help restore kidney function

The Plan

- Phase 3 clinical program received FDA and EMA guidance; trial underway
- Target commercial launch in 2026

The Mission

- Meaningfully reduce the number of people on dialysis or requiring transplantation each year
- Target population includes millions of diabetic CKD patients
- Potential indications expand up to 33 million patients in the U.S. and EU alone

World-class Leadership and Board of Directors

Dr. Tim Bertram, CEO

REGENMED Tx · Pfizer · inRegen · NexImmune

Dr. Deepak Jain, COO

REGENMED Tx · Baxter · Merck · J&J

James Coulston, CFO

TARGACEPT · EY

Dr. Libbie McKenzie, CMO

NaphCare

Dr. Joe Stavas,
SVP Clinical Development

Cornell Weill Cornell Medicine · Duke University · UNC School of Medicine

Dr. Darin Weber,
SVP Regulatory Development

Medeor Therapeutics · Biologics Consulting · mesoblast the adult stem cell company · FDA

Ashley Johns,
SVP Clinical Operations

REGENMED Tx · tengion Regenerative medicine brought to life · PMG Research

Todd Girolamo,
Chief Legal Officer & Secretary

caladrius Biosciences · LEERINK

Pablo Legorreta,
Chairman of the Board

Royalty Pharma · The Rockefeller University · Brown University · The New York Academy of Sciences · Open Medical Institute · Kidney Health Foundation · HSS · Lazard

Dr. Tim Bertram

William Doyle

novocure

Jennifer Fox

Nuvation Bio

Dr. Alan Lotvin

CVS Health

Dr. John Maraganore

Alnylam Pharmaceuticals

Dr. Brian Pereira

Visterra

bridgebio

Dr. Uma Sinha

José Ignacio Jiménez Santos

INBURSA Afore

World-class Leadership and Board of Directors

Dr. Tim Bertram, CEO

REGENMED Tx · Pfizer · inRegen · NexImmune

Dr. Deepak Jain, COO

REGENMED Tx · Baxter · Merck · J&J

James Coulston, CFO

TARGACEPT · EY

Dr. Libbie McKenzie, CMO

NaphCare

Dr. Joe Stavas,
SVP Clinical Development

Cincinnati Children's · Duke University · UNC School of Medicine

Dr. Darin Weber,
SVP Regulatory Development

Medeor Therapeutics · Biologics Consulting · mesoblast · FDA

Ashley Johns,
SVP Clinical Operations

REGENMED Tx · tengion · PMG Research

Todd Girolamo,
Chief Legal Officer & Secretary

caladrius · LEERINK

Joining us today

Pablo Legorreta,
Chairman of the Board

Royalty Pharma · The Rockefeller University · Brown University · The New York Academy of Sciences · Open Medical Institute · Kidney Health Foundation · HSS · Lazard

Dr. Tim Bertram

William Doyle

novocure

Jennifer Fox

Nuvation Bio

Dr. Alan Lotvin

CVS Health

Dr. John Maraganore

Alnylam

Dr. Brian Pereira

Visterra

bridgebio

Dr. Uma Sinha

José Ignacio Jiménez Santos

INBURSA Afore

REACT® Impact on Kidney Function

Preclinical Data Suggest REACT Treatment May Improve Kidney Function Via Multiple Mechanisms



Kelly et al, Am J Physiol Renal Physiol 299: F1026-F1039, 2010. Bruce et al, Regenerative Medicine 10(7), 2015
Preclinical studies in rodents and canines, data on file.

REACT® Goal: Restoration of Kidney Function

ProKidney's REACT Autologous Cell Therapy



Our Updates at Kidney Week 2022

- Further strong evidence for REACT's unique mechanism of action
  - Renal Epithelial Cells: an Elite Cell Platform for Kidney Regeneration
  - Selected Renal Cells Self-organize to Form Neo-nephrons and Attenuate Kidney Disease
  - Gene Ontology Reveals Potentially Unique Mechanism of Action Underlying Selected Renal Cells' Bioactivity
- Building a deeper CKD patient understanding
  - Prevalence of Chronic Kidney Disease (CKD): Comparison of Real-World Data (RWD) Sources to the USA National Health and Nutrition Examination Survey (NHANES)
  - Gender Differences in CKD Progression: Real-world Data (RWD) Analysis
  - SGLT2i Prescribers Among CKD Patients: Trends in Real-world Data (RWD)

REACT®: An Elite Cell Platform for Kidney Regeneration?

- Epithelial cells are the kidney's "workhorse"
- Demonstrate regenerative/modifying properties
- The "great communicator" cell in the kidney
- Pre-clinical improvement in renal function and mineralization
- Human embryologic lineage to progenitor cells
- Early signals of renal function improvement in humans
- Potential anchor platform for renal regeneration



From "Renal Epithelial Cells: an Elite Cell Platform for Kidney Regeneration?," Stavas et al, 2022

REACT®: An Elite Cell Platform for Kidney Regeneration?

Renal function in Phase 2 (RMCL-002) study

- Combined eGFR slope improved: -4.63 to -1.69 ml/min/1.73m²/year, p=0.015
- sCr eGFR slope improved: -3.98 to -1.27 ml/min/1.73m²/year, p=0.032
- Median follow up 24.3 months (IQR 18.8-27.7)
- 7 of 22 patients had a positive eGFR slope of +5.88 ml/min/1.73m²
- Log iPTH 0/8 to 0/19, p=0.04
- VEGF ELISA 4.32-7.39 ng/ml in CM



From “Renal Epithelial Cells: an Elite Cell Platform for Kidney Regeneration?” ASN Kidney Week, and Kidney Int. Rep, Stavas et al, 2022

Gene Ontology Reveals Potentially Unique Mechanism of Action Underlying Selected Renal Cells' Bioactivity



SRC/REACT™ in human cell culture, arrows point to expression of relevant markers

From "Gene Ontology Reveals Potentially Unique Mechanism of Action Underlying Selected Renal Cells' Bioactivity," Narayan et al, 2022
From "Selected Renal Cells Self-organize to Form Neo-nephrons and Attenuate Kidney Disease," Narayan et al, 2022

SRC Improves Kidney Microarchitecture



From “Selected Renal Cells Self-organize to Form Neo-nephrons and Attenuate Kidney Disease,” Narayan et al, 2022

Glomerulogenesis in Rodent Model



From “Selected Renal Cells Self-organize to Form Neo-nephrons and Attenuate Kidney Disease,” Narayan et al, 2022

Gene Ontology Reveals Potentially Unique Mechanism of Action Underlying Selected Renal Cells' Bioactivity

SRC / REACT:

- May be unique in expressing 8 important renal proteins
- Has gene products and signaling networks which appear compartmentalized within the tubules & glomeruli and participate in processes associated with kidney development
- In culture form organoids with self-assemble into tubules
- Is a standalone platform with nephrogenic potential which may underlie its renal restorative and reparative activity

From "Gene Ontology Reveals Potentially Unique Mechanism of Action Underlying Selected Renal Cells' Bioactivity," Narayan et al, 2022

REACT® May Rescue Highest-Risk Progressors before ESKD

Unrelenting Progression of CKD with No Available Cures



Standard of Care

- **Antihypertension**
  - ACEi
  - ARB
- **Glucose and Inflammation Reduction**
  - SGLT2i
  - DPP4
  - GLP-1
  - MRA

REACT® TARGETS

At this stage patients have minimal other treatment options and usually progress to ESKD, dialysis or transplantation

We are ProKidney

Novel Investigational Cell Therapy Platform in Late-stage Clinical Trials Aimed at Transforming CKD Treatment

- REACT autologous cell therapy currently conducting Phase 3 trials for diabetic CKD
- Pre-clinical through Phase 2 programs in additional indication
- 2019: Acquired technology in development since 2004
- 80+ employees
- $597M received from July 2022 business combination with Social Capital Suvretta Holdings III and concurrent PIPE
- Nasdaq-listed: PROK
- Top shareholder: Pablo Legorreta (~40% of shares outstanding); 4-year lockup on 50% of shares

Summary of Active Clinical Studies

Study	Objective	Status	Projected Data Readout
RMCL-002 (Ph2)	Safety & efficacy in Stage 3b/4 CKD	Fully enrolled	4Q 2023
REGEN-003 (Ph2)	Safety & efficacy in Stage 4/5 CKD	Fully enrolled	1H 2023
REGEN-007 (Ph2)	Bilateral injections Frozen product	Enrolling	2Q/3Q 2023
REGEN-006 / 016 (Ph3)	US Registration (006) OUS Registration (016)	Enrolling in U.S.	4Q 2024 (006)

Existing therapies slow the progression of CKD;
REACT's objective is to reverse it

Q&A

Selected Renal Cells Self-organize to Form Neo-nephrons and Attenuate Kidney Disease

- SRC / REACT forms organoids that assemble into tubules in culture in rat model
- The nephrogenic potential of SRC / REACT may underlie its renal reparative and restorative effects



From “Selected Renal Cells Self-organize to Form Neo-nephrons and Attenuate Kidney Disease,” Narayan et al, 2022